Concord Biotech Limited has intimated the stock exchanges about an upcoming meeting of its Board of Directors scheduled for Tuesday, October 27, 2026. The primary agenda of the meeting is to consider and approve the unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026. The financial results will be accompanied by a Limited Review Report issued by the company's Statutory Auditors.
The disclosure also confirms the continuation of the trading window closure previously communicated via letter dated September 28, 2026. Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct, the trading window for dealing in the company's securities will remain closed until 48 hours after the declaration of the financial results for Q2 and H1 FY27.